XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Operating activities    
Consolidated net loss $ (131,976) $ (9,668)
Adjustments to reconcile consolidated net loss to net cash used in operating activities    
Depreciation and amortization 763 878
Deferred income taxes 6
Net unrealized (loss) gain on investments - Hedge Funds 243 (3,433)
Impairment of investments - Other Pharmaceuticals 724
Impairment of cost method investment - Rafael Pharmaceuticals 79,141
Impairment - Altira 7,000
Provision for loss on receivable pursuant to line of credit 25,000
Equity in loss (earnings) of RP Finance 575 (192)
Provision for losses on related party receivables 10,095
Provision for doubtful accounts 37 104
Stock-based compensation (3,095) 719
Amortization of debt discount 250
Gain on sale of building (749)
Change in assets and liabilities:    
Trade accounts receivable (418) 39
Prepaid expenses and other current assets 172 157
Other assets 107 46
Accounts payable and accrued expenses 5,360 (933)
Other current liabilities 98 47
Due to related parties (79) 29
Due from Rafael Pharmaceuticals (120) (242)
Other liabilities 36 (59)
Net cash used in operating activities (13,811) (5,527)
Investing activities    
Purchases of property and equipment (62) (205)
Payment to fund RP Finance Line of Credit (1,875) (3,750)
Payment to Rafael Pharmaceuticals pursuant to Line of Credit (25,000)
Proceeds from sale of building 3,658
Proceeds related to distribution from Hedge Funds 2,000
Purchase of Investment in Altira (1,000)
Investment in Rafael Pharmaceuticals (9,123)
Net cash used in investing activities (26,937) (8,420)
Financing activities    
Contribution from noncontrolling interest of consolidated entity 912
Proceeds from exercise of options 43
Proceeds from issuance of common stock 104,167 13,000
Payment of transaction costs incurred in connection with sale of common stock (6,228)
Payments for taxes related to shares withheld for employee taxes (71) (146)
Net cash provided by financing activities 97,868 13,809
Effect of exchange rate changes on cash and cash equivalents, and restricted cash 51 18
Net increase (decrease) in cash and cash equivalents, and restricted cash 57,171 (120)
Cash and cash equivalents, and restricted cash, beginning of period 12,854 6,206
Cash and cash equivalents, and restricted cash, end of period 70,025 6,086
Supplemental schedule of noncash investing and financing activities    
Acquisition of additional ownership interest in LipoMedix 8
Reconciliation of cash and restricted cash    
Cash and cash equivalents 65,025 6,086
Restricted cash 5,000
Total cash and cash equivalents and restricted cash shown in statement of cash flows $ 70,025 $ 6,086